Anthropometric Measurements as Predictors of Low Birth Weight Among Tanzanian Neonates: A Hospital-Based Study
November 7, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
isturisa
Synonyms :
osilodrostat
Class :
Adrenal corticosteroid inhibitors
Brand Name :
isturisa
Synonyms :
osilodrostat
Class :
Adrenal corticosteroid inhibitors
Dosage Forms & StrengthsÂ
TabletÂ
1mgÂ
5mgÂ
10mgÂ
Initial dose
:
2
mg
Tablet
Orally 
twice a day
Titration:1 to 2mg twice a day initially, no more than two weeks
Maintenance dose:2-7mg twice a day
maximum dose-30mg
may enhance the serum concentration of CYP3A4 inhibitors
may enhance the serum concentration of CYP3A4 inhibitors
may enhance the serum concentration of CYP3A4 inhibitors
may enhance the serum concentration of CYP3A4 inhibitors
may enhance the serum concentration of CYP3A4 inhibitors
may enhance the serum concentration of CYP3A4 inhibitors
QTc interval is increased both by lenvatinib and osilodrosta
CYP3A strong enhancers of the small intestine may reduce the bioavailability of osilodrostat
OATP1B1/1B3 inhibitors increase the concentration of elagolix in the serum
OATP1B1/1B3 inhibitors increase the concentration of elbasvir and grazoprevir in the serum
OATP1B1/1B3 inhibitors increase the concentration of voxilaprevir in the serum
it increases the concentration of OATP1B1/1B3 substrates in the serum
may enhance the serum concentration of CYP3A4 inhibitors
may enhance the serum concentration of CYP3A4 inhibitors
may enhance the serum concentration of CYP3A4 inhibitors
may enhance the serum concentration of CYP3A4 inhibitors
may decrease the serum concentration
may decrease the serum concentration
may decrease the serum concentration
may decrease the serum concentration
may decrease the serum concentration
may increase the serum concentration
may increase the serum concentration
may increase the serum concentration
may increase the serum concentration
may increase the serum concentration
may decrease the serum concentration
may decrease the serum concentration
may enhance the serum concentration of CYP3A4 inhibitors
may enhance the serum concentration of CYP3A4 inhibitors
the effect of osilodrostat is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
may increase the levels serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) substrates
OATP1B1/1B3 inhibitors increase the concentration of brincidofovir in the serum
OATP1B1/1B3 inhibitors increase the concentration of eluxadoline in the serum
it may increase the levels of serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates
it may increase the levels of serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates
it may increase the levels of serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates
it may increase the levels of serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates
it may increase the levels of serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates
it may increase the levels of serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates
it may increase the levels of serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates
it may increase the levels of serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates
it may increase the levels of serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates
it may increase the levels of serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates
it may increase the levels of serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates
Frequency defined:Â Â
>10%Â
FatigueÂ
HeadacheÂ
NasopharyngitisÂ
ArthralgiaÂ
RashÂ
Blood corticotrophin increasedÂ
Abdominal painÂ
MyalgiaÂ
Abnormal hormone levelÂ
Urinary tract infectionÂ
PyrexiaÂ
CoughÂ
InfluenzaÂ
Adrenal insufficiencyÂ
NauseaÂ
EdemaÂ
VomitingÂ
Back painÂ
DiarrheaÂ
DizzinessÂ
HypokalemiaÂ
Decreased appetiteÂ
HypotensionÂ
AnemiaÂ
1-10%Â
AcneÂ
InsomniaÂ
DepressionÂ
AlopeciaÂ
ECG QT prolongationÂ
HirsutismÂ
DyspepsiaÂ
AnxietyÂ
GastroenteritisÂ
TachycardiaÂ
Increased transaminasesÂ
SyncopeÂ
Pregnancy consideration: DÂ
Lactation: Excretion of the drug in human breast milk is unknownÂ
Pregnancy category:Â
Category A: well-controlled and Satisfactory studies show no risk to the fetus in the first or later trimester.  Â
Category B: there was no evidence of risk to the fetus in animal studies, and there were not enough studies on pregnant women.Â
Category C: there was evidence of risk of adverse effects in animal reproduction studies, and no adequate evidence in human studies must take care of potential risks in pregnant women.   Â
Category D: adequate data available with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits.   Â
Category X: Drugs listed in this category outweigh the risks over benefits. Hence these categories of drugs need to be avoided by pregnant women.   Â
Category N: There is no data available for the drug under this categoryÂ
Patient information leafletÂ
Generic Name: osilodrostatÂ
Pronounced: [ O-sil-OH-droe-stat]Â
Why do we use osilodrostat?Â
It is used to treat Cushing’s diseaseÂ
Â
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
